Ocugen Inc. Stock Falls Tuesday, Underperforms Market
Ocugen Secures Data and Safety Monitoring Board Approval to Advance OCU410 Trial for Geographic Atrophy
Express News | Ocugen Inc - Dsmb Approves Continuation of Ocu410 Armada Phase 1/2 Study
Express News | Ocugen Inc: Ocu410 Has a Very Favorable Safety and Tolerability Profile
Express News | Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of Ocu410 Armada Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
104981603 : It shouldn't have reached the full decline point of around 0.55 for the big M head yet. The next support could be around 0.66, there might be some rebound.